China accepted the drug registration application of Shanghai Fosun Pharmaceutical (HKG:2196, SHA:600196) units Yaopharma and Jisimei (Wuhan) Pharmaceutical for their injectables, according to a Monday filing with the Hong Kong Exchange.
Yaopharma is the manufacturer of levofloxacin injection for mild, moderate, and severe bacterial infections such as hospital and community-acquired pneumonia, and other infections, the filing said.
Jisimei (Wuhan) Pharmaceutical manufactures cytarabine injection for acute myelogenous leukemia and other types of leukemia, the filing said.